Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $36.92.

Several brokerages have recently commented on JANX. Barclays upped their price objective on shares of Janux Therapeutics from $14.00 to $15.00 and gave the company an “underweight” rating in a research note on Friday. Guggenheim reduced their price target on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a report on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating on shares of Janux Therapeutics in a research report on Monday, October 19th. Wolfe Research upgraded Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price objective for the company in a report on Monday, August 24th. Finally, Truist Financial lifted their price objective on Janux Therapeutics from $26.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday.

Key Headlines Impacting Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $40 from $36 and reiterated its outperform rating, implying substantial upside from the cited $17.63 share price. Wedbush raises Janux price target
• Positive Sentiment: Truist raised its target to $27 from $26 and maintained a buy rating, signaling continued confidence in JANX. Truist analyst recommendations
• Positive Sentiment: Janux reported a third-quarter loss of $0.34 per share, narrower than analysts’ expected loss of $0.45–$0.47. Revenue of $9.29 million also exceeded the $8.03 million estimate. The results beat expectations, although the company remained loss-making. Janux third-quarter 2026 results
• Neutral Sentiment: Janux said it dosed the first patient in the Phase 1 study of JANX013 in combination with JANX007, marking progress in its clinical pipeline; the update does not establish how the treatment will perform. Janux business highlights
• Negative Sentiment: Barclays raised its target only to $15 from $14 but kept an underweight rating, placing its target below the cited share price and underscoring a bearish view that contrasts with other analysts. Barclays analyst recommendations

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Diversified Trust Co boosted its stake in Janux Therapeutics by 3.5% in the 3rd quarter. Diversified Trust Co now owns 17,429 shares of the company’s stock worth $301,000 after purchasing an additional 588 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Janux Therapeutics by 68.8% in the third quarter. Russell Investments Group Ltd. now owns 137,777 shares of the company’s stock worth $2,381,000 after acquiring an additional 56,176 shares during the period. Fulcrum Asset Management LLP grew its stake in shares of Janux Therapeutics by 3,391.2% in the third quarter. Fulcrum Asset Management LLP now owns 2,374 shares of the company’s stock worth $40,000 after acquiring an additional 2,306 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in shares of Janux Therapeutics by 25.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 209,002 shares of the company’s stock valued at $3,545,000 after purchasing an additional 42,910 shares during the last quarter. Finally, CenterBook Partners LP raised its holdings in shares of Janux Therapeutics by 39.1% during the third quarter. CenterBook Partners LP now owns 39,656 shares of the company’s stock valued at $685,000 after purchasing an additional 11,154 shares during the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

JANX stock opened at $17.63 on Tuesday. Janux Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.34. The firm’s fifty day moving average is $17.49 and its 200 day moving average is $15.42. The firm has a market cap of $1.08 billion, a P/E ratio of -11.09 and a beta of 2.44.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.13. The business had revenue of $9.29 million during the quarter, compared to the consensus estimate of $8.03 million. As a group, analysts forecast that Janux Therapeutics will post -1.70 EPS for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.